<9227> Microwave Chemistry 1055 +21
Rebound. They announced that they have welcomed Mr. Yoshitaka Ikeda, who served as the head of the Quantum Energy Division at the National Institutes for Quantum and Radiological Science and Technology until last year and developed a plasma heating system using high-power microwaves for research and development of fusion, as a technical advisor, and he has been well-received. With the participation of Mr. Ikeda, who has a lot of know-how in high-power oscillators and industrial connections, they plan to further accelerate development and complete oscillators of 500kW to 1 MW class by 2030.
<5246> ELEMENTS 1350 +122
Rebound. Liquid, a group company, announced that from August, it will enable personal identification using the IC chip of the My Number card from a web browser in the online personal identification service "LIQUID eKYC". This service provides an application that supports "App Clip", a function of the iPhone, to businesses that want to perform personal identification using the IC chip of personal identification documents such as public personal authentication (JPKI) using the My Number card and is regarded as good news.
<5027> AnyMind 1148 +26
Continuing its upward trend, it has been well-received that they have announced the launch of their 'EC mall and SNS review collection and analysis solution' on the data & artificial intelligence (ai) platform 'AnyAI'. This solution collects and analyzes consumer reviews and comments posted on EC malls and SNS, supporting the planning and execution of marketing strategies.
<4883> Modaris 70 +2
Even after rebounding, it's in a stalemate. It was announced that the company plans to announce data such as immune tolerance and sustained therapeutic effects of MDL-101 (epigenome editing technology using CRISPR) at the Fifth Next-Generation Gene Therapy Immunogenicity Summit. It is a data strongly indicating the safety of systemic administration of vectors expressing exogenous proteins, and suggests that MDL-101 has the potential to be an innovative therapeutic method for LAMA2-CMD and that CRISPR-GNDM is a groundbreaking technology platform applicable to systemic hereditary diseases.
<4592> Sun Bio 948 +150
2 consecutive days of limit-up. On the 24th, the regenerative medicine product, "Acugo intracerebral transplantation injection", was conditionally approved for manufacturing and sales by the Ministry of Health, Labor and Welfare, but additional data submission was requested and shipment approval was postponed. The company submitted additional data since March, and after evaluation, the approval was granted. The company explained that after about 2 more rounds of production, standard testing, and similar characteristic analysis to the additional data submitted since March, shipment will be possible after obtaining partial approval for changes in approval matters, and investor concerns seem to have subsided.
<4571> NanoMRNA 175 +1
It continues to rise significantly. After the end of trading on the 24th, it announced that the clinical results of a physician-initiated trial of PRDM14 siRNA, the company's pipeline, had been announced at the 28th Japanese Cancer Molecular Targeted Therapy Society. Ten patients with HER2-negative metastatic breast cancer were administered PRDM14 siRNA/YBC polymer complex, but no serious adverse effects were confirmed, and it was shown that the YBC polymer had clinical usefulness as an oligonucleotide drug delivery system, as well as being appreciated.